BR112017026709A2 - tratamento e diagnóstico de câncer - Google Patents

tratamento e diagnóstico de câncer

Info

Publication number
BR112017026709A2
BR112017026709A2 BR112017026709A BR112017026709A BR112017026709A2 BR 112017026709 A2 BR112017026709 A2 BR 112017026709A2 BR 112017026709 A BR112017026709 A BR 112017026709A BR 112017026709 A BR112017026709 A BR 112017026709A BR 112017026709 A2 BR112017026709 A2 BR 112017026709A2
Authority
BR
Brazil
Prior art keywords
cancer
sting
cgas
cell
therapy
Prior art date
Application number
BR112017026709A
Other languages
English (en)
Inventor
N Barber Glen
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of BR112017026709A2 publication Critical patent/BR112017026709A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)

Abstract

a presente descrição proporciona, em geral, um método para selecionar uma terapia para o tratamento de câncer em um indivíduo humano e, subsequentemente, tratar o câncer em um indivíduo, que inclui o isolamento de uma célula de câncer de um indivíduo humano com câncer, determinar a atividade funcional de sting ou cgas na célula; e selecionar uma terapia para o câncer com base na atividade funcional do sting ou cgas na célula. também é fornecido, se a atividade funcional de sting e / ou cgas for definida como defeituosa na célula, a terapia selecionada é aquela que é efetiva em matar células cancerosas deficientes em sting e / ou deficientes em cgas, por exemplo, terapia incluindo a administração ao sujeito de um vírus oncolítico.
BR112017026709A 2015-06-11 2016-06-13 tratamento e diagnóstico de câncer BR112017026709A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562174374P 2015-06-11 2015-06-11
PCT/US2016/037288 WO2016201450A2 (en) 2015-06-11 2016-06-13 Cancer treatment and diagnosis

Publications (1)

Publication Number Publication Date
BR112017026709A2 true BR112017026709A2 (pt) 2018-08-28

Family

ID=57504666

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026709A BR112017026709A2 (pt) 2015-06-11 2016-06-13 tratamento e diagnóstico de câncer

Country Status (8)

Country Link
US (3) US20180169159A1 (pt)
EP (1) EP3307329A4 (pt)
JP (1) JP2018519278A (pt)
KR (1) KR20180027516A (pt)
AU (1) AU2016277149A1 (pt)
BR (1) BR112017026709A2 (pt)
CA (1) CA2989157A1 (pt)
WO (1) WO2016201450A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3429596T3 (da) 2016-03-18 2022-10-24 Immune Sensor Llc Cykliske dinukleotide forbindelser og brugs metoder
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
US11629346B2 (en) * 2017-06-12 2023-04-18 University Of Miami Sting-dependent activators for treatment of disease
WO2019123414A1 (en) * 2017-12-22 2019-06-27 Straximm Llp Engineered viruses expressing cyclic gmp-amp synthase
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2020023361A1 (en) * 2018-07-23 2020-01-30 H. Lee Moffitt Cancer Center And Research Institute Inc. Enhancing anti-tumor response in melanoma cells with defective sting signaling
CA3131130A1 (en) * 2019-03-06 2020-09-10 Generation Bio Co. Non-active lipid nanoparticles with non-viral, capsid free dna
EP3946338A1 (en) * 2019-03-29 2022-02-09 Kura Oncology, Inc. Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
EP3987291A1 (en) * 2019-06-21 2022-04-27 IFM Due, Inc. Methods of treating cancer
JPWO2021024897A1 (pt) * 2019-08-05 2021-02-11
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
CN117412745A (zh) * 2020-12-22 2024-01-16 艾福姆德尤股份有限公司 治疗癌症的方法
WO2022183044A1 (en) * 2021-02-25 2022-09-01 Duke University Methylation markers for the treatment of glioblastoma and other cancers
JP2024521048A (ja) * 2021-05-19 2024-05-28 スティンジン，インコーポレイテッド Ｓｔｉｎｇシグナル伝達組成物の小分子阻害剤および使用の方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039730D1 (de) * 1999-02-05 2008-09-11 Arch Dev Corp Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
US9233157B2 (en) * 2002-02-14 2016-01-12 Gholam A. Peyman Method and composition for hyperthermally treating cells
DK1984007T3 (en) * 2006-02-13 2015-12-07 Oncolytics Biotech Inc Application of Low-dose local immunosuppression for amplification of viral oncolytic therapy
EP2073823A1 (en) * 2006-10-13 2009-07-01 Medigene AG Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
JP5187676B2 (ja) * 2007-06-27 2013-04-24 国立大学法人名古屋大学 腹腔内腫瘍病変の治療又は予防用の医薬組成物
EP2942357A1 (en) * 2008-08-04 2015-11-11 Glen N. Barber Sting (stimulator of inteferon genes), a regulator of innate immune responses
KR102255996B1 (ko) * 2012-12-19 2021-05-26 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 포유동물 시클릭 디-뉴클레오티드 신호 경로의 약학적 표적화

Also Published As

Publication number Publication date
WO2016201450A3 (en) 2017-01-19
KR20180027516A (ko) 2018-03-14
JP2018519278A (ja) 2018-07-19
CA2989157A1 (en) 2016-12-15
US20180169159A1 (en) 2018-06-21
US20210046133A1 (en) 2021-02-18
EP3307329A4 (en) 2019-05-15
AU2016277149A1 (en) 2018-02-01
US20190314429A1 (en) 2019-10-17
WO2016201450A2 (en) 2016-12-15
EP3307329A2 (en) 2018-04-18
US10821142B2 (en) 2020-11-03

Similar Documents

Publication Publication Date Title
BR112017026709A2 (pt) tratamento e diagnóstico de câncer
PE20180260A1 (es) Metodos y kits para tratar la depresion
BR112018068906A2 (pt) composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
BR112015015131A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, e produto
BR112015023203A8 (pt) métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
BR112015022378A2 (pt) método para identificar uma área de um coração humano, sistema para identificar uma área de um coração humano, método para definir um acionador de uma fonte associada a um distúrbio de ritmo cardíaco de um coração humano, e, sistema para definir um acionador de uma fonte associada a um distúrbio de ritmo cardíaco de um coração humano
BR112016003868A2 (pt) método, aparelho, mídia de armazenamento não transitório, e, programa de computador
BR112019006918A2 (pt) proteínas actriib variantes e usos das mesmas
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
EA201790504A1 (ru) Монослой мононуклеарных клеток периферической крови или клеток костного мозга и его применение
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112018003238A2 (pt) seleção de pacientes para terapia de combinação
BR112014029346A2 (pt) sistema e método implementado por computador para a montagem de um plano de tratamento médico
BR112017024431A2 (pt) método de tratamento de um ebv-lpd
BR112017006113A2 (pt) combinações sinérgicas de auristatina
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
CO2020008863A2 (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato
GB2554591A (en) Clinical support system and method

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]